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SHORT COMMUNICATION
Dacarbazine (DTIC), human recombinant interferon alpha 2a (Roferon)
and 5-fluorouracil for disseminated malignant melanoma
N.H. Mulder, E.G.E. de Vries, D.Th. Sleijfer, H. Schraffordt Koops & P.H.B. Willemse
Departments ofMedical and Surgical Oncology, University Hospital Groningen, The Netherlands
The combination of Dacarbazine (DTIC) with alpha-
interferon has consistently shown a 30% remission rate in
patients with disseminated malignant melanoma (Thomson et
al., 1987; Guillou et al., 1989; Mulder et al., 1990). Although
some of these remissions, in particular the complete remis-
sions are prolonged, overall results are not satisfactory.
Recently, a synergistic effect has been described between
5-fluorouracil (5-FU) and alpha-interferon in vitro (Elias &
Cussman, 1988), particularly in colon carcinoma in vivo
(Wadler et al., 1989), but also in a patient with melanoma
metastatic to the cerebrum (Jacobs et al., 1989).
We have tested the combination of alpha-interferon
(Roferon), 5-FU and DTIC in 26 patients with disseminated
malignant melanoma.
Eligible for treatment were patients with histologically pro-
ven disseminated malignant melanoma, who had not received
previous sytemic therapy before, had progressive disease, and
gave informed consent.
Excluded were patients with evidence of central nervous
system metastasis on presentation, or uncontrolled other
diseases.
Work-up consisted of chest X-ray, liver echography or CT
scanning, blood chemistry and physical examination before
every course and monthly in case of remission.
Chemotherapy consisted of intravenous DTIC, 750 mg m2
day 1 and every 4 weeks, intravenous 5-FU 1,000 mg m-2 on
day 14 and every 4 weeks. Roferon was given daily in a dose
of 9 million units subcutaneously, the first 3 days 3 million
units were given. One course was 4 weeks of treatment,
tumour response was evaluated after every two courses, treat-
ment was stopped in case of progression, otherwise six
courses were given.
Dose modification consisted of giving interferon on altern-
ating days as long as necessary to alleviate symptoms, and
25% dose reduction of DTIC in case of grade 3 or more
haematological toxicity, or nausea.
Evaluation of toxicity followed the WHO guide lines
(WHO Handbook, 1979). A complete response was defined
as the complete disappearance of all signs of disease, a
partial response as the decrease in the sum of the product of
perpendicular diameters of all measurable tumour lesion of at
least 50%, without progression of any lesion or development
of new lesions. A response had to last a minimum of 1 month.
Progressive disease was defined as an increase in the product
of parameters of more than 25%, or formation of new
lesions.
Twenty-six patients received a total of 111 courses. Patient
characteristics are given in Table I. Median age of the
patients was 44 years, range 15-57 years.
Toxicity was mainly due to nausea and vomiting after
DTIC in the first 14 patients, but this toxicity was completely
abolished when ondansetron was introduced (8 mg i.v.) prior
to infusion. Five patients had thrombocytopenia and/or
leukopenia grade 3. Disabling fatigue requiring interferon
dose adjustment occurred in five patients. No mucositis or
diarrhoea occurred.
None of the patients developed signs or symptoms of brain
metastases during treatment or follow-up in case of response.
Fourteen patients had progressive disease, two stabilisation
of previous progressive disease for 12 + and 4 + months.
Five patients had a partial remission of 2, 2, 10 +, 2 + and
4 + months. Five patients had a complete response of 2, 4, 6,
8 + and 13 + months. Median survival in all patients is 12
months.
Of the 11 female patients, six responded, with three com-
plete remissions. The 38% response rate (95% confidence
level 20-59%) is not suggestive of a major impact on re-
sponse from the addition of 5-FU, in the magnitude of
triplication as suggested in the first reports on synergism
between interferon and 5-FU (Wadler et al., 1989).
Previously, we reported a response rate of the two drugs of
35% (95% confidence 19-55%) (Mulder et al., 1990). Also,
in colon cancer the combined response rate of 5-FU and
interferon is levelling off to a more modest synergism
(Wadler et al., 1991).
However, the absence of development of brain symptoms
during treatment and in the follow-up of responders is strik-
ing in comparison to our previous experience, when 18 of 62
patients developed such symptoms (Mulder et al., 1989;
Mulder et al., 1990). This finding might confirm the observa-
tion of a response of cerebral melanoma localisation follow-
ing 5-FU and interferon (Jacobs et al., 1989). In the dose
used here 5-FU has no important organ toxicity, although it
might add to the fatigue induced by interferon. The 38%
response rate also confirms the somewhat higher response
rate of the combination of DTIC and interferon when com-
pared to each drug separately (McClay & Mastrangelo, 1988;
Creagan et al., 1987).
Although the majority of responses is quite short, this
study confirms that occasionally complete responses can be
prolonged and very worthwhile, especially if they can be
reached with relatively untoxic treatment. In that respect the
toxicity profile of DTIC containing regimens has changed
dramatically following the introduction of ondansetron as an
antiemetic. Most of our patients considered the 5-FU





High volumea 18 6






Lymph nodes 8 2
aHigh volume: >4 lesions or a lesion >3 cm.
Correspondence: N.H. Mulder, M.D., Department of Medical
Oncology, University Hospital, Oostersingel 59, 9713 EZ Groningen,
The Netherlands.
Received 8 August 1991; and in revised form 30 September 1991.
'." Macmillan Press Ltd., 1992 Br. J. Cancer (1992), 65, 303-304304 N.H. MULDER et al.
infusion, without ondansetron prophylaxis, as the more toxic
one in comparison to DTIC.
In an interim report on this study (Mulder et al., 1991),
eight responses were seen in the first 12 patients, in the next
14 patients only two partial responses were seen. In our
study, this difference coincided with the introduction of
ondansetron, however a causal relation is unlikely. An
important predictor of response seems to be sex, and more
female patients were entered during the first part of the
study.
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